Cargando…

Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib

Vismodegib, an inhibitor of the Hedgehog signaling pathway, is an approved drug for monotherapy in locally advanced or metastatic basal cell carcinoma (BCC). Data on combined modality treatment by vismodegib and radiation therapy, however, are rare. In the present study, we examined the radiation se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hehlgans, Stephanie, Booms, Patrick, Güllülü, Ömer, Sader, Robert, Rödel, Claus, Balermpas, Panagiotis, Rödel, Franz, Ghanaati, Shahram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164565/ https://www.ncbi.nlm.nih.gov/pubmed/30142876 http://dx.doi.org/10.3390/ijms19092485

Ejemplares similares

Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome
por: Booms, Patrick, et al.
Publicado: (2015)

Tumor Suppressor Protein p53 and Inhibitor of Apoptosis Proteins in Colorectal Cancer—A Promising Signaling Network for Therapeutic Interventions
por: Güllülü, Ömer, et al.
Publicado: (2021)

Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study
por: Altay-Langguth, Alev, et al.
Publicado: (2021)

Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer
por: Müller von der Grün, Jens, et al.
Publicado: (2018)

Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
por: von der Grün, Jens, et al.
Publicado: (2019)

C-Reactive Protein-to-Albumin Ratio as Prognostic Marker for Anal Squamous Cell Carcinoma Treated With Chemoradiotherapy
por: Martin, Daniel, et al.
Publicado: (2019)

Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site – current status and challenges
por: Müller von der Grün, Jens, et al.
Publicado: (2017)

Peripheral Leukocytosis Is Inversely Correlated with Intratumoral CD8+ T-Cell Infiltration and Associated with Worse Outcome after Chemoradiotherapy in Anal Cancer
por: Martin, Daniel, et al.
Publicado: (2017)

Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences
por: Balermpas, P, et al.
Publicado: (2014)

Patterns of care, toxicity and outcome in the treatment of salivary gland carcinomas: long-term experience from a tertiary cancer center
por: von der Grün, Jens, et al.
Publicado: (2021)

Dexamethasone Treatment Limits Efficacy of Radiation, but Does Not Interfere With Glioma Cell Death Induced by Tumor Treating Fields
por: Linder, Benedikt, et al.
Publicado: (2021)

The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis
por: Hehlgans, Stephanie, et al.
Publicado: (2015)

The dawn of hedgehog inhibitors: Vismodegib
por: Sandhiya, Selvarajan, et al.
Publicado: (2013)

A non-linear detection of phospho-histone H2AX in EA.hy926 endothelial cells following low-dose X-irradiation is modulated by reactive oxygen species
por: Large, Martin, et al.
Publicado: (2014)

Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Arsenic Trioxide and (−)-Gossypol Synergistically Target Glioma Stem-Like Cells via Inhibition of Hedgehog and Notch Signaling
por: Linder, Benedikt, et al.
Publicado: (2019)

Inhibition of CAL27 Oral Squamous Carcinoma Cell by Targeting Hedgehog Pathway With Vismodegib or Itraconazole
por: Freitas, Raíza Dias, et al.
Publicado: (2020)

Vismodegib: the Proof of Concept in Basal Cell Carcinoma
por: Berrada, Narjiss, et al.
Publicado: (2014)

Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer
por: Balermpas, P, et al.
Publicado: (2014)

Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer
por: Balermpas, P, et al.
Publicado: (2014)

Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma
por: von der Grün, Jens, et al.
Publicado: (2019)

Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib
por: Su, Maxwell G., et al.
Publicado: (2020)

Treatment of Locally Advanced Basal Cell Carcinomas with Vismodegib
por: Mastronardi, Luis, et al.
Publicado: (2021)

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia
por: Mesti, Tanja, et al.
Publicado: (2022)

Metastatic same-site squamous cell carcinoma arising during vismodegib therapy for basal cell carcinoma
por: Zhao, Raymond, et al.
Publicado: (2022)

Fractionation-Dependent Radiosensitization by Molecular Targeting of Nek1
por: Freund, Isabel, et al.
Publicado: (2020)

Extent of Neck Dissection and Cervical Lymph Node Involvement in Oral Squamous Cell Carcinoma
por: Thoenissen, Philipp, et al.
Publicado: (2022)

Differential effects of α-catenin on the invasion and radiochemosensitivity of human colorectal cancer cells
por: Förster, Sarah, et al.
Publicado: (2018)

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
por: Cowey, C. Lance
Publicado: (2013)

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib
por: Batty, Nicolas, et al.
Publicado: (2012)

Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
por: Martins, Pedro Carvalho, et al.
Publicado: (2019)

Hedgehog signaling pathway: A novel target for cancer therapy: Vismodegib, a promising therapeutic option in treatment of basal cell carcinomas
por: Abidi, Afroz
Publicado: (2014)

Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial
por: von der Grün, Jens, et al.
Publicado: (2022)

Heat shock protein 70 and tumor‐infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK‐ROG)
por: Stangl, Stefan, et al.
Publicado: (2017)

Evaluation of Hedgehog Pathway Inhibition on Nevoid Basal Cell Carcinoma Syndrome Fibroblasts and Basal Cell Carcinoma-Associated Fibroblasts: Are Vismodegib and Sonidegib Useful to Target Cancer-Prone Fibroblasts?
por: Eibenschutz, Laura, et al.
Publicado: (2021)

Immunomodulatory Properties and Molecular Effects in Inflammatory Diseases of Low-Dose X-Irradiation
por: Rödel, Franz, et al.
Publicado: (2012)

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib
por: Thacker, Curtis A, et al.
Publicado: (2012)

Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma
por: Macha, Muzafar A, et al.
Publicado: (2013)

Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma
por: Aditya, Suruchi, et al.
Publicado: (2013)

Rapid response to vismodegib in a patient with advanced basal cell carcinoma
por: Vornicova, Olga, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3gfpah9uki2i322o9lf0u0ro0c